Kuros Biosciences Ltd.

Earnings Release • Oct 21, 2010

News Details

Corporate | 21 October 2010 07:00

National Institutes of Health, SAIC, and Cytos Biotechnology Collaborate on Malaria Vaccines Research

Cytos Biotechnology AG / Key word(s): Research Update

21.10.2010 07:00

Publication of a media release

Schlieren (Zurich), Switzerland, October 21, 2010 - Cytos Biotechnology Ltd
(SIX:CYTN) announced today that it has been awarded a subcontract by
Science Applications International Corporation (SAIC) to support the U.S.
National Institutes of Health (NIH) with the preclinical development of a
malaria vaccine with the National Institute of Allergy and Infectious
Diseases (NIAID). Cytos will provide its virus-like particle (VLP) based
vaccination technology and expertise while the NIH will contribute malaria
antigen candidates. Vaccines generated by Cytos will be tested in
preclinical models of malaria disease by NIH and SAIC. This project has
been funded in whole or in part with Federal funds from the National
Institute of Allergy and Infectious Diseases, under Contract No.
N01-AI-05421.

Dr Martin Bachmann, CSO of Cytos Biotechnology commented 'We are excited
and honored to work with the NIH, the world's biggest health institute, as
a partner for development of new vaccines to prevent malaria, a major
threat to people living in at risk areas as well as to travelers visiting
these regions. This collaboration is the second infectious disease vaccines
partnership with leading research institutes of the world following recent
announcement of our flu vaccines collaboration with academic institutes in
Singapore. This new collaboration demonstrates the continuing
attractiveness of the VLP-platform for partnering in the eyes of leading
biomedical organizations in academia and industry'.

About Malaria

More than 40 percent of the world's population lives in areas where there
is a risk of contracting malaria. Nearly one million people die of malaria
every year, mostly infants, young children and pregnant women and most of
them in Africa. Approximately 300-500 million cases of clinical malaria
occur each year. Malaria accounts for at least $12 billion in economic
losses each year in Africa, and a reduction in annual economic growth
estimated at 1.3 percent. (Source: NIH Website)

About NIH

The US National Institutes of Health is made up of 27 different components
called Institutes and Centers. Each has its own specific research agenda.
All but three of these components receive their funding directly from the
US Congress, and administrate their own budgets. NIH's mission is to seek
fundamental knowledge about the nature and behavior of living systems and
the application of that knowledge to enhance health, lengthen life, and
reduce the burdens of illness and disability.

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 79 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'will be tested', 'candidates' or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
therapeutic entities will enter clinical trials, that clinical trial
results will be predictive for future results, that therapeutic entities
will be the subject of filings for regulatory approval, that any drug
candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.

Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 47 03
Fax. +41 44 733 47 04
e-mail: wolfgang.renner@cytos.com
www.cytos.com

21.10.2010 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in München, Berlin, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX

End of Announcement EquityStory News-Service

---